3 completed, 1 terminated, 1 unknown. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow ARYx Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation ATI-5923, Coumadin (warfarin) - Atrial Fibrillation, Atrial Flutter | Phase 2 / Phase 3 | Unknown | ARYx Therapeutics | 600 | 2008-05-01 | 2010-02-02 |
| A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome Placebo, 20 mg ATI 7505, 40 mg ATI 7505 - Post Prandial Distress Syndrome | Phase 2 | Terminated | Procter and Gamble | 6 | 2008-02-01 | 2009-06-17 |
| Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation ATI-5923 - Atrial Fibrillation | Phase 2 | Completed | ARYx Therapeutics | 60 | 2006-12-01 | 2007-11-08 |
| Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers ATI-2042, ATI-2042 200 mg - Atrial Fibrillation | Phase 2 | Completed | ARYx Therapeutics | 72 | 2006-07-01 | 2009-03-11 |
| Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers ATI-7505, Placebo - Healthy | Phase 1 / Phase 2 | Completed | Mayo Clinic | 48 | 2005-01-01 | 2010-03-29 |
Atrial Fibrillation (3) · Atrial Flutter (1) · Cardiomyopathies (1) · Myocardial Infarction (1)
ATI 7505 (2) · tecarfarin (2) · Warfarin (1) · celivarone (1)
United States (5) · Canada (2) · United Kingdom (1)
Bruce C Yacyshyn, MD (1) · Dave Ellis, M.D., Ph.D (1) · Michael Camilleri, MD (1) · Michael Ezekowitz, MBChB, PhD (1) · Olga Bandman, MD (1)